Last reviewed · How we verify
Saline 0.9%
Saline 0.9% is an isotonic sodium chloride solution that restores and maintains fluid and electrolyte balance in the body.
Saline 0.9% is an isotonic sodium chloride solution that restores and maintains fluid and electrolyte balance in the body. Used for Fluid and electrolyte replacement in dehydration, Intravenous fluid maintenance and resuscitation, Wound irrigation and topical cleansing.
At a glance
| Generic name | Saline 0.9% |
|---|---|
| Also known as | sterile saline, Placebo, placebo, Hydration, Placebo for GLP-1 |
| Sponsor | Rigshospitalet, Denmark |
| Drug class | Crystalloid fluid / Electrolyte replacement |
| Modality | Small molecule |
| Therapeutic area | General/Supportive Care |
| Phase | FDA-approved |
Mechanism of action
Normal saline (0.9% NaCl) is a physiologic solution with osmolarity matching blood plasma, allowing safe intravenous or topical administration without causing cell lysis or crenation. It serves as a fundamental fluid replacement therapy to correct dehydration, maintain intravascular volume, and support electrolyte homeostasis across multiple clinical settings.
Approved indications
- Fluid and electrolyte replacement in dehydration
- Intravenous fluid maintenance and resuscitation
- Wound irrigation and topical cleansing
- Vehicle for intravenous drug administration
Common side effects
- Hyperchloremic acidosis (with prolonged high-volume infusion)
- Fluid overload / pulmonary edema (in susceptible patients)
- Hypernatremia (rare, with excessive administration)
Key clinical trials
- Effect of Lidocaine Infusion Versus Dexmedemidine Infusion on the Neurocognitive Function of Elderly Patients Undergoing Endoscopic Retrograde Cholangiopancreatography(ERCP): a Randomized, Controlled Trial. (NA)
- PRP Injection Into the Sacroiliac Joint After Ipsilateral THA: Effects on Early Recovery and Function (SIJ-THA Randomized Trial) (NA)
- Pulse Glucocorticoid Therapy in Patients With ST-Segment Elevation Myocardial Infarction (PHASE2)
- Magnesium Supplementation in Advanced Non-small Cell Lung Cancer (NSCLC) (PHASE2, PHASE3)
- Thumb Base Osteoarthritis: Ultrasound-guided Platelet-rich Plasma Versus Placebo Injection (PHASE2)
- Safety Evaluation of PfSPZ Vaccine in Pregnant Women in Mali (MalVIP1) (PHASE1)
- Individual Response to Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Treatment of Peritoneal Carcinomatosis From Peritoneal Mesothelioma or Atypical Mesothelial Proliferation or From Ovarian, Colorectal, or Appendiceal Histologies (PHASE1)
- Impact of Sugammadex Versus Neostigmine on Early Postoperative Pulmonary Function (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Saline 0.9% CI brief — competitive landscape report
- Saline 0.9% updates RSS · CI watch RSS
- Rigshospitalet, Denmark portfolio CI